深圳恩瑞恺诺生物技术

Enruikai Biotechnology is a China-based biotechnology company dedicated to developing next-generation off-the-shelf CAR-NK cell therapies for cancer treatment. The company utilizes its proprietary En-NK platform to overcome technical hurdles in NK cell expansion and genetic engineering, aiming to create potent therapies for solid tumors like ovarian and liver cancer. By focusing on allogeneic NK cells, Enruikai seeks to provide more accessible, safer, and cost-effective alternatives to autologous CAR-T therapies. The firm is supported by leading investors including Matrix Partners China and IDG Capital, positioning it as a key player in the emerging field of innate immune cell engineering.